BR112022020438A2 - Composições compreendendo três proteínas de fusão ospa para uso médico - Google Patents

Composições compreendendo três proteínas de fusão ospa para uso médico

Info

Publication number
BR112022020438A2
BR112022020438A2 BR112022020438A BR112022020438A BR112022020438A2 BR 112022020438 A2 BR112022020438 A2 BR 112022020438A2 BR 112022020438 A BR112022020438 A BR 112022020438A BR 112022020438 A BR112022020438 A BR 112022020438A BR 112022020438 A2 BR112022020438 A2 BR 112022020438A2
Authority
BR
Brazil
Prior art keywords
compositions
ospa
fusion proteins
medical use
ospa fusion
Prior art date
Application number
BR112022020438A
Other languages
English (en)
Inventor
Bézay Nicole
Hochreiter Romana
Lundberg Urban
Russell Bailey Steven
Sybil Anderson Annaliesa
Ute Jansen Kathrin
Alfred Scott Daniel
Original Assignee
Valneva Austria Gmbh
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Austria Gmbh, Pfizer filed Critical Valneva Austria Gmbh
Publication of BR112022020438A2 publication Critical patent/BR112022020438A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

COMPOSIÇÕES COMPREENDENDO TRÊS PROTEÍNAS DE FUSÃO OSPA PARA USO MÉDICO. A presente invenção refere-se a uma composição compreendendo a proteína de fusão OspA de SEQ ID NO: 1 (LipS1D1-S2D1), a proteína de fusão OspA de SEQ ID NO: 2 (Lip-S4D1-S3hybD1) e a proteína de fusão OspA de SEQ ID NO : 3 (Lip-S5D1-S6D1) para uso em uma vacina ou para uso em um método para induzir uma resposta imune em um ser humano contra a doença de Lyme.
BR112022020438A 2020-04-09 2021-04-09 Composições compreendendo três proteínas de fusão ospa para uso médico BR112022020438A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20169148 2020-04-09
EP20169147 2020-04-09
EP20169642 2020-04-15
EP20187283 2020-07-22
EP20202816 2020-10-20
US202163152582P 2021-02-23 2021-02-23
PCT/US2021/026599 WO2021207615A1 (en) 2020-04-09 2021-04-09 Compositions comprising three ospa fusion proteins for medical use

Publications (1)

Publication Number Publication Date
BR112022020438A2 true BR112022020438A2 (pt) 2022-11-29

Family

ID=75581705

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022020438A BR112022020438A2 (pt) 2020-04-09 2021-04-09 Composições compreendendo três proteínas de fusão ospa para uso médico

Country Status (11)

Country Link
US (1) US20230173051A1 (pt)
EP (1) EP4132950A1 (pt)
JP (1) JP2023522170A (pt)
KR (1) KR20220167305A (pt)
CN (1) CN115698044A (pt)
AU (1) AU2021254265A1 (pt)
BR (1) BR112022020438A2 (pt)
CA (1) CA3174892A1 (pt)
IL (1) IL297166A (pt)
MX (1) MX2022012647A (pt)
WO (1) WO2021207615A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023212520A1 (en) 2022-04-25 2023-11-02 Pfizer Inc. Compositions and methods for eliciting an immune response protective against lyme disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2015104396A1 (en) 2014-01-09 2015-07-16 Valneva Austria Gmbh Mutant fragments of ospa and methods and uses relating thereto
US20230151063A1 (en) * 2017-04-13 2023-05-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto

Also Published As

Publication number Publication date
IL297166A (en) 2022-12-01
WO2021207615A1 (en) 2021-10-14
CA3174892A1 (en) 2021-10-14
AU2021254265A1 (en) 2022-11-03
MX2022012647A (es) 2023-01-16
EP4132950A1 (en) 2023-02-15
KR20220167305A (ko) 2022-12-20
US20230173051A1 (en) 2023-06-08
CN115698044A (zh) 2023-02-03
JP2023522170A (ja) 2023-05-29

Similar Documents

Publication Publication Date Title
Basto et al. Targeting TLR2 for vaccine development
UY39060A (es) Composiciones y métodos para prevenir y tratar la infección por coronavirus - vacunas sars-cov-2
BRPI0407877A (pt) conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente
JP6874031B2 (ja) アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法
Singh et al. A Plasmodium falciparum 48/45 single epitope R0. 6C subunit protein elicits high levels of transmission blocking antibodies
Martinez-Campos et al. Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against Trypanosoma cruzi infection in mice
Earnhart et al. An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences
ES2581981T3 (es) Polipéptidos de Streptococcus suis y polinucleótidos codificantes de los mismos y su utilización en aplicaciones vacunales y diagnósticas
BR0312537A (pt) Usos de hidrolisato de proteìna de soro em composição comestìvel, método de indução da saciedade em seres humanos ou animais e método de melhoria ou controle da percepção da imagem do corpo e/ou controle do peso do corpo e/ou controle da ingestão de calorias e/ou auxìlio na adesão a um plano de dieta
NO20111324A1 (no) Rekombinant MVA-virus
BRPI0905725B1 (pt) vacina e embalagem farmacêutica
Rafati et al. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients
Pacífico et al. Immunization with Schistosoma mansoni 22.6 kDa antigen induces partial protection against experimental infection in a recombinant protein form but not as DNA vaccine
Solioz et al. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis
BRPI0415315A (pt) métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou derivado bioativos, e de uma composição imunogênica
CN101451145B (zh) 基于t细胞表位的结核基因疫苗及其制备方法和应用
de Souza et al. Vaccination of Balb/c mice against experimental visceral leishmaniasis with the GP36 glycoprotein antigen of Leishmania donovani
BR112022020438A2 (pt) Composições compreendendo três proteínas de fusão ospa para uso médico
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
MX2014004132A (es) Señuelos humanos notch1.
BR112021020777A2 (pt) Vacina de subunidade do csfv
Horká et al. Tick saliva affects both proliferation and distribution of Borrelia burgdorferi spirochetes in mouse organs and increases transmission of spirochetes to ticks
RU2020106669A (ru) Синтетические белки и пути их терапевтического применения
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
BR112023004819A2 (pt) Composições de vacinas multivalentes e seus usos